Cardinal Health (CAH) Stock News, Jan-Jun 2025

Cardinal Health (NYSE: CAH) has launched the Kendall DL™ Multi System in the U.S., a new medical device that enables continuous monitoring of cardiac activity, blood oxygen level, and temperature through a single connection point. This single-patient use monitoring system features innovative cable management and is designed to accompany patients throughout their hospital stay. The system's proprietary design reduces false alarms and motion-related artifacts in ECG tracings, while its single-use nature helps minimize cross-contamination risks. The device incorporates clinically proven technology to enhance patient care efficiency and can be reprocessed through Cardinal Health, potentially improving healthcare providers' financial performance.

Cardinal Health (NYSE: CAH) has released its 2025 Advanced Therapies Report, providing comprehensive insights into the cell and gene therapy (CGT) industry. The report, based on a survey of over 100 healthcare providers, reveals that the advanced therapy industry is projected to have over 200 therapies approved and treat more than 100,000 U.S. patients by 2030.

Key findings highlight significant challenges in CGT adoption, with 56% of respondents citing financial constraints and 54% pointing to inadequate reimbursement as major barriers. The report emphasizes the need for improved collaboration across industry stakeholders, with 69% of respondents supporting strategic initiatives between payers and manufacturers. Additionally, 64% identified insufficient social support as the primary reason patients don't receive needed CGT treatments.

Cardinal Health (NYSE: CAH) has announced a dividend increase, with the new quarterly dividend set at $0.5107 per share. The dividend will be paid on July 15, 2025, to shareholders who are on record as of July 1, 2025. The payment will be made from the company's capital surplus.

Cardinal Health (NYSE: CAH) reported strong Q3 FY25 results with flat revenue at $54.9 billion, but showing 19% growth excluding a customer contract expiration. GAAP operating earnings rose to $730 million with EPS of $2.10, while non-GAAP operating earnings increased 21% to $807 million with EPS of $2.35. The company demonstrated growth across all operating segments, with Pharmaceutical and Specialty Solutions profit up 14% to $662 million, Global Medical Products and Distribution profit up 77% to $39 million, and Other segment profit rising 22% to $134 million. Based on strong performance, Cardinal Health raised its FY25 non-GAAP EPS guidance to $8.05-$8.15 from $7.85-$8.00 and anticipates double-digit non-GAAP EPS growth in FY26.

Cardinal Health (NYSE: CAH) has announced it will release its third-quarter financial results for fiscal year 2025 on May 1, 2025, before the New York Stock Exchange opens. The company will host a webcast discussion of the results at 8:30 a.m. Eastern.

Investors can access the webcast and accompanying slide presentation through Cardinal Health's Investor Relations page without requiring an access code. The presentation materials and webcast replay will remain available on the company's Investor Relations page for 12 months following the event.

Cardinal Health (NYSE:CAH) has announced two significant additions to its Board of Directors, effective March 7, 2025. Robert Musslewhite, former CEO of Definitive Healthcare Corp., and Sudhakar Ramakrishna, current President and CEO of SolarWinds , have been elected as independent directors.

Musslewhite, with over 20 years of leadership experience, brings expertise in healthcare analytics and technology. He will serve on the board's Audit and Human Resources and Compensation Committees. Ramakrishna, a global technology leader with extensive cybersecurity experience, will join the Audit and Risk Oversight Committees.

Both appointments strengthen Cardinal Health's technological capabilities and strategic oversight. Musslewhite's background includes CEO roles at OptumInsight and The Advisory Board Company, while Ramakrishna's experience spans leadership positions at companies including Pulse Secure, Citrix Systems, and Polycom.

Cardinal Health (NYSE: CAH) has announced that its Board of Directors has approved a quarterly dividend payment. The company will distribute $0.5056 per share from its capital surplus. Shareholders who are recorded as owners at the close of business on April 1, 2025, will receive the dividend payment on April 15, 2025.

Cardinal Health (CAH) reported Q2 FY25 revenues of $55.3 billion, a 4% decrease from Q2 FY24, though revenue increased 16% excluding a large customer contract expiration. GAAP operating earnings rose 9% to $549 million, with GAAP diluted EPS at $1.65. Non-GAAP operating earnings grew 9% to $635 million, driven by Pharmaceutical and Specialty Solutions segment.

The company raised its FY25 non-GAAP EPS guidance to $7.85-$8.00 from $7.75-$7.90. Notable developments include completing acquisitions of 73% ownership in GI Alliance and Integrated Oncology Network. Pharmaceutical segment profit increased 7% to $531 million, while Global Medical Products segment profit rose to $18 million.

Cardinal Health (NYSE: CAH) announced the construction of a new 340,000 square foot distribution center in Fort Worth, Texas, supporting its at-Home Solutions business. The facility will consolidate two existing warehouses, adding 74,000 square feet of inventory capacity while retaining current workforce. The center will ship approximately 10,000 packages daily to patients nationwide.

The facility will feature advanced technology including 74 robots, a 1,500-foot automated conveyor system, and four automated box-making machines producing 500 custom boxes hourly. It will utilize a cloud-based warehouse management system with AI capabilities for inventory management. The company reported its best-ever metrics in quality, service, efficiency, and employee safety in Q1 FY2025. The facility is expected to be fully operational by Summer 2025.